Cite
HARVARD Citation
Shafrin, J. et al. (2018). An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?. Health policy. 122 (6), pp. 607-613. [Online].